Compare LRN & INDV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LRN | INDV |
|---|---|---|
| Founded | 2000 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 4.4B |
| IPO Year | 2007 | 2014 |
| Metric | LRN | INDV |
|---|---|---|
| Price | $90.49 | $41.18 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $106.75 | N/A |
| AVG Volume (30 Days) | 871.9K | ★ 1.6M |
| Earning Date | 04-28-2026 | 06-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 26.87 | ★ 8100.00 |
| EPS | ★ 5.39 | 0.69 |
| Revenue | $917,734,000.00 | ★ $1,239,000,000.00 |
| Revenue This Year | $6.18 | N/A |
| Revenue Next Year | $4.74 | N/A |
| P/E Ratio | ★ $16.75 | $57.96 |
| Revenue Growth | 3.29 | ★ 4.29 |
| 52 Week Low | $60.61 | $15.00 |
| 52 Week High | $171.17 | $42.81 |
| Indicator | LRN | INDV |
|---|---|---|
| Relative Strength Index (RSI) | 52.09 | 63.02 |
| Support Level | $87.15 | $35.36 |
| Resistance Level | $103.08 | $42.81 |
| Average True Range (ATR) | 3.18 | 1.50 |
| MACD | 0.55 | -0.00 |
| Stochastic Oscillator | 81.27 | 67.31 |
Stride Inc is an American online educational company. It offers alternative programs to traditional on-campus schooling. It also operates state-funded virtual charter schools around the United States. The educational programs for K-12 students are usually monitored by parents and provide virtual classroom environments where teachers meet with students online, by phone, or in-person. The company's contractual agreements with various school districts to offer its curriculum programs provide a majority of the company's revenue. The company lines of business are Managed Public School Programs, Institutional and Private Pay Schools and Other.
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).